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a  b  s  t  r  a  c  t
Adverse  reactions  and  non-response  are  common  in patients  treated  with thiopurine  drugs.  Current  mon-
itoring  of  drug  metabolite  levels  for guiding  treatment  are  limited  to analysis  of thioguanine  nucleotides
(TGNs)  in  erythrocytes  after  chemical  derivatisation.  Erythrocytes  are  not  the  target  tissue  and  TGN
levels  show  poor  correlations  with  clinical  response.  We  have  developed  a sensitive  assay  to  quantify
deoxythioguanosine  (dTG) without  derivatisation  in the  DNA  of nucleated  blood  cells.  Using liquid chro-
matography  and  detection  by  tandem  mass  spectrometry,  an  intra-  and  inter-assay  variability  below
7.8%  and  17.0%  respectively  were  achieved.  The  assay  had  a detection  limit  of 0.0003125  ng (1.1 femto-
moles)  dTG  and  was  quantified  in DNA  samples  relative  to  endogenous  deoxyadenosine  (dA) in  a  small





(AZA)  therapy  for more  than  25  weeks.  These  patients  had  dTG  levels  of  20–1360  mol  dTG/10 mol  dA;
three  patients  who  had  not  started therapy  had  no detectable  dTG. This  method,  comparable  to previous
methods  in  sensitivity,  enables  the  direct  detection  of  a cytotoxic  thiopurine  metabolite  without  derivati-
sation  in an easily  obtainable,  stable  sample  and  will  facilitate  a better  understanding  of the  mechanisms
of  action  of  these  inexpensive  yet  effective  drugs.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Since their introduction into clinical practice more than
ix decades ago, the purine analogues mercaptopurine (MP;
,7-dihydropurine-6-thione), azathioprine (AZA; 6-[3-methyl-
-nitroimidazol-4-yl]sulfanyl-7H-purine) and thioguanine (TG;
-amino-3,7-dihydropurine-6-thione) have been used extensively
Abbreviations: ALL, Acute childhood leukemia; 6-MP or MP, 6-mercaptopurine;
ZA, azathioprine; IBD, inflammatory bowel disease; MeMP,  methylmercaptop-
rine; MeMP-d3, Methymercaptopurine-D3; TIMP, thioinosine monophosphate;
IDP, thioinosine diphosphate; TITP, thioinosine triphosphate; TXMP, thioxan-
hine monophosphate; TGMP, thioguanosine monophosphate; TGDP, thioguanosine
iphosphate; TGTP, thioguanosine triphosphate; IMPDH, inosine-monophosphate
ehydrogenase; TPMT, thiopurine methyl-transferase; HGPRT, hypoxanthine-
uanine phosphoribosyl transferase; ITPase, inosine tri-phosphatase; GMPS,
uanosine monophosphate synthetase; dTG, deoxythioguanosine; TGN, thiogua-
ine nucleotide; NBCs, nucleated blood cells; CD, Crohn’s disease; UC, ulcerative
olitis; RBC, red blood cell; QC, Quality control.
∗ Corresponding author. Institute of Cellular Medicine, Newcastle University,
edical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
E-mail address: sally.coulthard@newcastle.ac.uk (S.A. Coulthard).
ttp://dx.doi.org/10.1016/j.jchromb.2016.06.017
570-0232/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
in the treatment of diseases such as acute childhood leukaemia
(ALL) [1], inflammatory bowel disease (IBD) [2,3], auto-immune
hepatitis [4] and rheumatoid arthritis [5]. Thiopurines require
activation by hypoxanthine-guanine phosphoribosyl transferase
(HGPRT, E.C. 2.4.2.8) followed by multi-step metabolism to TGNs
or methylated products to exert their clinical effect (Fig. 1).
Two key enzymes mediating thiopurine metabolism are inosine-
monophosphate dehydrogenase (IMPDH) which is only present in
nucleated cells [6], and thiopurine methyltransferase (TPMT) [7–9].
If treated with normal thiopurine doses, patients lacking TPMT
activity develop high TGN levels that can lead to life-threatening
leukopenia [10–12]. Cytotoxicity is mediated by a variety of mech-
anisms, including inhibition of de novo purine synthesis, disruption
of G-protein signalling [13] and incorporation of thioguanine
nucleotides (TGNs) into DNA with subsequent mismatching to
thymidine, causing cell death by post-replicative mismatch repair
[14–16].Given a low therapeutic index and the wide variation in clin-
ical response, including potential for life-threatening toxicity in
patients with very low or absent TPMT activity, it is important to
monitor and optimise thiopurine drug levels. Assays have been
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Mass transitions and optimised MS/MS  parameters for analyte quantification, deoxythioguanosine (dTG), deoxyadenosine (dA), Methymercaptopurine-D3 (MeMP-d3).
Analyte Analyte Retention Time (min) MRM  transition (m/z) Declustering Potential (V) Entrance Potential (V) Collision Energy (eV) Collision exit potential (V)
dTG 6 284.19 −> 168.2 41 
dA  5.6 252.30 −> 136.2 31 
MeMP-d3 6.9 170.1 −> 152.2 66 
Fig. 1. Schematic summarising the metabolism of 6- MP  via the enzymes (Blue text)
inosine-monophosphate dehydrogenase (IMPDH), thiopurine methyl-transferase
(TPMT), hypoxanthine-guanine phosphoribosyl transferase (HGPRT), inosine tri-
phosphatase (ITPase) and guanosine monophosphate synthetase (GMPS). MeMP,
methylmercaptopurine; TIMP, thioinosine monophosphate with metabolism to the
di-  and triphosphates TIDP and TITP, respectively; TXMP, thioxanthine monophos-





























(ri-phosphates TGDP and TGTP, respectively and incorporation into DNA (for inter-
retation of the references to colour in this figure legend, the reader is referred to
he web  version of this article).
eveloped to measure metabolites in a range of cellular com-
artments including erythrocytes [17–20], whole blood [21] and
eukocyte DNA [22,23] but ease of access to erythrocytes coupled
ith simple HPLC separation techniques has meant that quan-
ifying thiopurine metabolites in erythrocytes has become the
tandard method for therapeutic monitoring. However, despite its
alue for assessing patient compliance, there is significant debate
bout concordance with therapeutic response in IBD [24–26].
on-concordance can arise from methodological issues [27] and
ifferences in metabolism between nucleated versus enucleated
ells which lack the critical IMPDH enzyme. Therefore, the incorpo-
ation of deoxythioguanosine (dTG) into the DNA of nucleated cells
ay  be a more relevant marker of therapeutic response. The aim of
his study was to develop a sensitive assay for DNA-incorporated
TG in nucleated blood cells which could be developed for clinical
se to study the mechanisms of response to thiopurines.
. Materials and methods
.1. Chemicals and enzymes
The dTG standard was from Carbosynth (Compton, UK);
eoxyadenosine (dA) was from Sigma-Aldrich (Gillingham, UK) and
euterated 6-methylmercaptopurine (MeMP-d3) from Toronto
esearch Chemicals (Ontario, Canada). HPLC grade acetic acid was
rom Fisher Scientific (Loughborough, UK). Calf intestinal alkaline
hosphatase and nuclease P1 from Penicillium citrinum were from
igma-Aldrich, as were all other reagents..2. Patient blood sample collection and processing
Clinical samples were from a small cohort of adult IBD patients
10 with Crohn’s Disease [CD] and 10 Ulcerative Colitis [UC]) treated10 15 10
10 21 8
10 33 10
with a range of doses of AZA, all of whom had been in clinical
remission for more than 6 months with no therapeutic complica-
tions; three untreated IBD patients were used as controls. The study
protocol was  approved by NRES Committee South West − Corn-
wall & Plymouth, Bristol Research Ethics Committee Centre. DNA
was isolated from whole blood collected in EDTA tubes, or from
negative-control MOLT4 (T-acute lymphoblastic leukaemia) cells,
using previously published methods [28]. Briefly whole blood was
mixed with 3 vols of ice-cold buffer A (10 mM Tris, 320 mM sucrose,
5 mM Mg  Cl2 1% Triton × 100 pH 8) and centrifuged at 1730g for
10 min  at 4 ◦C. The supernatant was  removed and the remaining
pellet re-suspended in 1 mL  buffer B (400 mM Tris, 60 mM EDTA,
150 mM NaCl and 1% SDS pH 8) plus 0.5 mL  of 5 M sodium perchlo-
rate, mixed for 10 min, then incubated at 65 ◦C for 45 min. To this,
2.5 mL  of chloroform was  added and mixed for 20 min prior to cen-
trifugation at 432g for 10 min  at 4 ◦C. The top layer was  removed and
2.5 vols of ethanol added to precipitate the DNA which was spooled
out, air-dried and re-suspended in 100–200 L of double-deionised
water. The red blood cell (RBC) TGN assays were performed by a
commercial laboratory at the City Hospital Birmingham (cityas-
says.org). Other tests were part of routine clinical care at the six
hospitals contributing samples.
DNA was  digested with P1 nuclease and alkaline phosphatase
to release nucleosides for LC–MS/MS analysis using previously-
described methods [29]. Briefly, samples were prepared in the
following manner: 5 g DNA in a total volume of 100 L
double-deionised water, containing 124.38 ng/mL (0.735 M)
Methymercaptopurine-D3 (MeMP-d3) as an internal standard to
control for extraction efficiency, was  denatured by heating to 100
◦C for 5 min. After chilling on ice for 2 min, 10 L of 10X digestion
buffer (500 mM sodium acetate, 10 mM MgCl2 pH 5.3) and 5 L
of 0.12U/L nuclease P1 was added and incubated for 1 h at 50
◦C. Finally, 20 L of 1 M Tris-HCl and 1 L of alkaline phosphatase
(1U/mL) were added to each sample and incubated for 30 min  at
40 ◦C. MeMP-d3 was  used as an internal standard as it was  the
only deuterated thiopurine metabolite available commercially at
the time.
2.3. LC–MS/MS analysis of thioguanine incorporated into DNA
Chromatographic separation of dTG, dA and MeMP-d3 was
achieved using a Prominence HPLC (Shimadzu, Kyoto, Japan) with
an XSelect HSS T3 4.6 × 100 mm 3.5 m and a VanGuard car-
tridge 3.9 × 5 mm 3.5 m guard column (Waters, Massachusetts,
USA) maintained at 30 ◦C. Analytes were eluted with HPLC grade
(Sigma-Aldrich) mobile phases comprising 0.05% aqueous formic
acid (A) and 0.05% formic acid in acetonitrile (B). The flow rate was
0.5 mL/min and the mobile phase system consisted of a starting
condition of 1% buffer B increasing to 3% at 1.1 min, 8% at 2.4 min
and increasing to a maximum of 30% at 4.1 min  then decreasing to
5% at 4.5 min, maintained until 5.5 min  then decreasing to 1% for
an equilibration period of 2.5 min. An API4000 triple quadrupole
LC–MS/MS (Applied Biosystems, California, USA) was  used for anal-
ysis with electrospray ionisation performed in positive ion mode
using nitrogen gas with the following optimum settings: curtain
gas, 20; ion source gas 1, 10; ion source gas 2, 10; ion spray voltage,
5500; collision gas, 6; entrance potential, 10; ionisation tempera-
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Table  2
Standard curve and quality control analyses.
Analyte dA dTG
LOD (ng injected) a ndf 0.0003125
LLOQ (ng) b ndf 0.000625
analytical  range (ng injected) 0.0975 ng to 50 ng 0.000625 ng–10 ng
average curvec Y = −6218126 ×2 + 26200326x + 5014429 y = 263992 × + 148.9
weighting 1/x2 1/x
fit  quadratic linear
Intra-day High QCd 3.5% 4.2%
Intra-day Mid  QC 7.8% 7.7%
Intra-day Low QC 3.3% 11.9%
Inter-day High QCe 7.8% 8.2%
Inter-day Med  QC 5.1% 8.5%
Inter-day Low QC 17.0% 15.9%
a Limit of detection (10 × baseline).
b Lower Limit of Quantification (2 × LOD).
c Calibration curves adjusted R2: dA = 0.991; dTG = 0.996.






































Fig. 2. LC–MS/MS profiles (50 L injection volume) for (a) dA and dTG standards
(125 ng/mL dA and 0.78 ng/mL dTG; peak areas represent 6.25 ng dA and 0.039 ng
injected dTG), and (b) a patient on treatment with azathioprine. The additional smalld Intra-day, n = 10.
e Inter-day, n = 5.
f nd, not determined: dA standard concentrations were 100-fold higher than for 
ure, 300◦C. Mass transitions and optimised MS/MS  parameters for
nalyte quantification are summarised in Table 1.
Standards were prepared at 100,000 ng/mL dA and 2000 ng/mL
TG before serial dilution in double-deionised water to 390 ng/mL
A and 3.9 ng/mL dTG, respectively, after which dA standards
ere diluted 1/100 and dTG standards 1/10 in double-deionised
ater prior to injection. Quality controls (QCs) were diluted using
0 × digestion buffer as for patient samples at three concentra-
ions; these were then diluted either 1/10 (for dTG) or 1/100
for dA) in double-deionised water to yield concentrations of
igh (40,000 ng/mL dA: 400 ng/mL dTG), medium (4000 ng/mL dA:
0 ng/mL dTG) and low (400 ng/mL dA: 4 ng/mL dTG) concentration
tandards prior to injection.
Standards and controls, as for patient samples, contained
24.38 ng/mL MeMP-d3 prior to 1/10 or 1/100 dilution. Samples
ere diluted in double-deionised water 1/10 (for dTG determina-
ion) and 1/100 (for dA) to avoid signal saturation on the mass
pectrometer. Sample injections represented 0.2 g patient DNA
er injection for dTG determination and 0.02 g DNA for dA. Stan-
ards were analysed in duplicate, QCs in triplicate, and negative
ontrol MOLT4 DNA and samples were analysed in singlicate, all
ith a 50 L injection volume. Samples where the internal stan-
ard was outside an acceptable range (within 15% of the expected
alue) were discarded. For measurement of dTG, background at the
etention time for dTG in extracts of negative control MOLT4 DNA
loaded as for patient DNA) was subtracted from the dTG peak in
atient samples (Fig. 2).
.4. LC–MS/MS validation
Method validation was adapted from the 2001 FDA guidelines
30]. Not all validation parameters could be determined because
alibrators consisting of dTG incorporated into DNA are not obtain-
ble and it is not possible to have a processed sample containing
he DNA matrix without the presence of dA.
.4.1. Selectivity
As dA is always present in processed DNA samples, the absence
f dTG in negative-control MOLT4 cells and in patients not on thiop-
rine therapy indicates selectivity.
.4.2. Accuracy and precision
QC solutions of analytes were prepared in DNA digestion buffer
t the concentrations 400, 40 and 4 ng/mL for dTG and 40,000, 4000
nd 400 ng/mL for dA, equating to 2, 0.2 and 0.02 ng for dTG and 20,
 and 0.2 ng for dA per injection, and used to determine intra- (5peak in (b) between the dA and dTG peaks is thioguanosine. The retention time of
the internal standard MeMP-d3 (not shown) was 6.92 min.
separate analytical runs containing 5 QCs per concentration) and
inter-assay (10 QCs per concentration) accuracy and precision from
multiple injections (Table 2).
2.4.3. Recovery and sample dilution
It is not possible to obtain matrix free of dA, and the addition
of exogenous calibrators would not be a suitable equivalent mea-
sure of the efficiency of extraction from DNA; therefore, we could
not perform a full recovery analysis. The testing of different DNA
extracts from the same sample and different amounts of DNA from
the same sample gave a stable ratio between dA and dTG (Table 3)
and this indicates that extraction efficiency is maintained across
both analytes.
2.4.4. Freeze and thaw stability
QC solutions of analytes were prepared in DNA digestion buffer
as described above at the concentrations 400, 40 and 4 ng/mL for
dTG and 40,000, 4000 and 400 ng/mL for dA, stored at −20 ◦C and
subjected to between 1 and 3 freeze thaw cycles, each of 24 h
duration. The QCs were then thawed and analysed on the same
analytical run following the third freeze thaw cycle. All results were
within 15% of expected values (Table 4).
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Table  3
Consistent results using different starting amounts of DNA for digestion from the
same sample. N/D, not detected.
Amount of DNA
digested (g)
ng dAa detected ng dTGb Moles dTG/106
moles dA
5 10.1 0.059 520.7
2.5  5.6 0.031 493.4
1.25  2.5 0.013 461.9
0.625 1.4 0.006 398.2
Untreated control patient 8.5 N/D N/D
DNA  range meanc Stdev CV
1.25  − 5ug 49.20 2.94 6%
0.625 − 5ug 46.86 5.27 11%
a Representing 0.018 g DNA injected.
b Representing 0.18 g DNA injected.




LQC MQC  HQC LQC MQC HQC
FT1a 0% 0% 0% 0% 0% 0%
FT2a −3% 12% 4% 1% −1% 8%
FT3a −6% 4% 9% −10% −13% −12%
%CV  across all samples 3% 6% 5% 6% 8% 11%
aSignal change compared to FT cycle 1.
Table 5
Low temperate stability.
Moles dTG/106 moles dA % difference between days






ILQC 105.231 88.495 −16%
MQC  66.707 68.164 2%
HQC 77.813 86.026 10%.4.5. Short-Term temperature stability
QC solutions of analytes were prepared in DNA digestion buffer
t the concentrations 400, 40 and 4 ng/mL for dTG and 40,000,
able 6
uantification of incorporated dTG (amount detected in 50 L sample, representing 0.18 
ID  1–20) treated with azathioprine (dose) and three untreated patients (A–C). ID, patien
ID Diseasea dose ng dAb ng dTG moles dTG/106 moles dA fmoles dTG
1 CD 100 3.97 0.003 59.2 52.0 
2  UC 150 9.25 0.035 333.2 682.2 
3  UC 150 3.115 0.001 20.2 13.9 
4  UC 125 7.4 0.011 135.4 221.8 
5  CD 200 4.62 0.027 524.1 535.9 
6  UC 150 4.555 0.005 97.4 98.2 
7  CD 150 14.7 0.022 133.3 433.8 
8  UC 100 6.1 0.003 36.3 49.1 
9  CD 100 4.185 0.004 74.2 68.7 
10  CD 50 7.35 0.002 26.5 43.2 
11  UC 150 11.4 0.006 46.7 117.8 
12  UC 200 6.2 0.013 178.8 245.4 
13  CD 42 11.95 0.024 181.1 479.0 
14  UC 25 5.15 0.008 129.2 147.2 
15  CD 200 6.45 0.002 27.5 39.3 
16  CD 150 4.77 0.005 89.3 94.2 
17  UC 175 1.785 0.019 921.7 364.2 
18  UC 100 7.2 0.032 393.6 627.2 
19  CD 75 14.45 0.007 44.5 142.3 
20  CD 200 3.125 0.048 1359.5 940.3 
A  UC 0 10 N/D N/D N/D 
B  UC 0 9.6 N/D N/D N/D 
C  CD 0 8.45 N/D N/D N/D 
a Crohn’s Disease, CD; Ulcerative colitis UC.
b Representing 0.018 g DNA injected.
c Normal ranges: White cell count (WCC), 4–11 × 109/L; Neutrophils (Neut), 2.5–7.5 × 1
U/L;  TPMT, 70–110 mU/L; RBC TGNs, reference range 235–450 pmol/8 × 108 RBC.gr. B 1028 (2016) 175–180
4000 and 400 ng/mL for dA and tested after 24 h incubation at 4
◦C (Table 5).
2.5. Statistical analysis
Data were analysed using R [31]. Residuals from linear and
non-linear models of dTG versus drug dose were not normally
distributed (Shapiro-Wilks test, P < 0.01) and, therefore, non-
parametric Kendall’s rank correlation [32] was used for all analyses.
3. Results
We  report here a sensitive LC–MS/MS method for measuring,
without derivatisation, the thiopurine metabolite, dTG, in DNA iso-
lated from whole blood of patients with CD or UC treated with AZA
(Fig. 2). The method range was from 0.0975 ng to 50 ng injected for
dA and from 0.000625 ng to 10 ng injected for dTG, with R2 > 0.99
for the standard curves (Table 2). There was  no matrix effect and
no concentration effect on the ratio between dTG and dA (Table 3).
Three quality controls containing standards made in digestion
buffer at low, medium and high concentrations within the stan-
dard curve range (duplicates at each concentration per run) were
included in all runs; the intra-day variation was <7.8% and 11.9%
for dA and dTG, respectively, and the inter-day variation was <17.0%
and 15.9% for dA and dTG, respectively (Table 2). The limit of detec-
tion (LOD) for dTG standards was  0.0003125 ng and lowest limit of
quantification (LLOQ) 0.000625 ng (Table 2). In the patient samples,
dA was  at very high concentrations and, therefore, in the standard
mixtures dA was used at 100-fold higher levels than dTG to achieve
appropriate standard curve ranges for both analytes, and samples
were diluted 10-fold for dA determination relative to dTG determi-
nation. Incorporation of dTG into the DNA was  reported as moles
dTG per 106 moles dA, after subtraction of background at the dTG
retention time using digested DNA from untreated MOLT4 cells,
and was  detectable in 0.2 g patient DNA per LC–MS/MS injection.
Patients included were established on AZA therapy for more than
6 months and were in clinical remission according to the treating
g DNA, injected onto column) in NBC in relation to clinical parameters from patients
t identifier; N/A, data not available; N/D, analyte not detected.
/g DNA WCCc Neutc ALTc APc TPMT RBC TGNc RBC MMPc
10.9 9.4 10 60 70 N/A N/A
5.4 3.3 20 50 70 N/A N/A
4.3 3 29 89 87 N/A N/A
3.8 2.4 5 42 14 N/A N/A
3.4 2.2 21 37 70 N/A N/A
9.3 5.1 16 94 123 N/A N/A
5.5 3.6 13 52 102 N/A N/A
5 3 13 70 78 N/A N/A
9 8 11 63 80 N/A N/A
10.5 8.3 18 91 102 N/A N/A
8 4 15 86 81 148 412
5.8 4.1 22 71 N/A 296 6698
5 2.9 14 16 N/A 522 0
3.8 2.7 16 78 N/A 318 0
9.2 9 8 80 94 559 0
8 5.7 16 64 92 120 221
7.8 5.7 13 58 N/A 293 363
3.3 2.4 15 80 116 477 219
6.3 4 15 100 100 80 320
5.1 3 28 45 94 169 6398
4.6 3.2 26 202 126 N/A N/A
3.6 2.3 19 52 134 N/A N/A
12.3 10.2 20 85 81 N/A N/A









































































[S.A. Coulthard et al. / J. Chro
hysician. For this cohort of patients, the incorporated dTG levels
aried from 20 to 1360 mol  dTG/106 moles dA; expressed in the
nits used by Jacobson et al. [33], this represents 14–940 fmol/g
NA (median 113; Table 6). Within this small group of patients
here was no significant positive correlation between dTG levels
nd drug dose (Kendall’s rank correlation coefficient P = 0.143),
lthough further studies with a larger sample size are warranted.
here were no indications for potential relationships between dTG
evels and RBC TGN measurements (Kendall, P = 0.85) or TPMT
ctivity (Kendall, P = 0.72). Patients who were not on AZA treatment
ad no detectable dTG in their DNA (Table 6).
. Discussion
The method presented here has good sensitivity for dTG detec-
ion in DNA from whole blood with dTG levels expressed relative to
n endogenous reference (dA) for sample loading; only 0.2 g DNA
as required per injection, with intra- and inter-assay calibration
rovided by commercially available standards. Using this approach,
e were able to quantify DNA-incorporated dTG directly in the DNA
f adult patients with IBD. Jacobsen et al. [33] have developed a
imilar assay but this requires derivatisation before analysis, neces-
itating standard dTG-incorporated DNA to control for variation in
he derivatisation reaction. Nevertheless, both methods appear to
ave comparable sensitivity with respect to analyte detection.
For the samples from children with ALL treated with MP  Jacob-
on et al. [33] reported incorporated dTG amounts of 45–1190 fmol
G/g DNA (median 377). Ebbesen et al. [34] reported similar val-
es for standard- and intermediate risk childhood ALL patients
n the NOPHO-ALL2008 protocol [35]. For the adult IBD patients
eported here, DNA-incorporated dTG quantities, expressed in the
ame units, were 14–940 fmol/g DNA. The MP  dose (NOPHO-
LL2008 protocol [35]) received by patients whose samples were
sed by Ebbesen et al. [34] was similar to guidelines for adult IBD
atients [36]. Therefore, incorporated dTG amounts were, on the
hole, comparable in these childhood ALL and adult IBD patients
sing different methods, despite differences in disease biology and
atient age. Using their derivatisation assay [33], Ebbesen et al.
34] reported that DNA-TGNS were independent of TPMT status in
hildhood/adolescent ALL patients on maintenance therapy with
-MP. This was also the case for the IBD patients investigated here,
ut, unlike Jacobson et al. [33], we found no correlation between
BC TGN levels and DNA-incorporated dTG in whole blood DNA
f IBD patients. Such a lack of correlation is not surprising given
he very different cellular compartments and the fact that clini-
al studies have shown major difference between RBC TGNs and
eukocyte cytosolic TGNs in the same blood samples [37,38]. Dis-
ase biology may  also be an important factor and it is critical to
nderstand thiopurine metabolism in relevant target tissues and
ow this relates to pharmacological markers and clinical responses.
ith the method described here, sample processing, DNA isolation,
igestion and analysis are simple and easily set up in diagnos-
ic laboratories, and this will facilitate a greater understanding of
hiopurine pharmacology which is essential if these inexpensive
et effective drugs are to be used to their full potential.
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